When.com Web Search

  1. Ads

    related to: does eliquis prevent stroke

Search results

  1. Results From The WOW.Com Content Network
  2. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa.

  3. Is Eliquis Covered by Medicare? - AOL

    www.aol.com/eliquis-covered-medicare-140000963.html

    Eliquis is an anticoagulant used to lower the chance of stroke in people with atrial fibrillation. ... also used to prevent or treat blood clots in the legs, also known as deep vein thrombosis ...

  4. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

    www.aol.com/news/2013-01-02-us-fda-approves...

    U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...

  5. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

    www.aol.com/news/2012-10-01-eliquis-apixaban...

    ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...

  6. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    [4] [5] [6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non-valvular atrial fibrillation (AF) who have other risk factors, and prevent blood clots after routine knee and hip replacement surgery. [2] [3] [7]

  7. Direct thrombin inhibitor - Wikipedia

    en.wikipedia.org/wiki/Direct_thrombin_inhibitor

    Dabigatran is an oral direct thrombin inhibitor. Dabigatran (Pradaxa) was found to be noninferior to Warfarin in prevention of ischemic stroke, as well as intracranial hemorrhage risk and overall mortality for non-valvular atrial fibrillation according to the RE-LY trial. [9]